Form 4: KalVista CEO Sells Shares for Tax Obligations

KalVista Pharmaceuticals CEO Benjamin L. Palleiko sold 10,034 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

Summary

• Benjamin L. Palleiko, Chief Executive Officer and Director of KalVista Pharmaceuticals, Inc. (KALV), reported transactions involving company stock.
• On February 21, 2026, 23,250 restricted stock units (RSUs) settled, converting into 23,250 shares of common stock.
• Following this, on February 23, 2026, Palleiko sold 10,034 shares of common stock at a weighted average price of $15.5668 per share.
• This sale was explicitly stated as a 'sell to cover' transaction to satisfy tax withholding obligations related to the RSU vesting and was not a discretionary sale.
• After these transactions, Palleiko beneficially owns 442,883 shares of common stock and 279,000 restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale of shares was a non-discretionary 'sell to cover' transaction to satisfy tax withholding obligations, which is a routine occurrence for executive equity compensation.

Future Outlook

NA

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are common for executives receiving equity compensation and are generally not indicative of a change in management's confidence in the company's future prospects, unlike discretionary sales.

Stakeholder Impact

• Shareholders: Slight reduction in direct insider ownership, but the non-discretionary nature of the sale mitigates concerns about management's confidence.

Key Dates

Recommendation

The reported transactions are routine 'sell to cover' actions by an executive to satisfy tax obligations upon RSU vesting, not a discretionary sale indicating a change in sentiment. Therefore, it does not provide new information that would warrant a change in investment recommendation based solely on this filing.

Keywords

KalVista Pharmaceuticals, KALV, Form 4, Insider Trading, Benjamin L. Palleiko, CEO, Restricted Stock Units, RSU, Stock Sale, Tax Withholding